复发胶质瘤患者入组早期临床试验的基因组驱动医学
该研究回顾了2008至2018年间入组早期临床试验的88例复发胶质瘤患者,其中45例(51.1%)接受分子导向治疗。在高级别胶质瘤患者中,分子导向组疾病稳定≥6个月及部分或完全缓解率为25.7%,非分子导向组为5.1%(p=0.02)。分子富集策略与更长总生存相关(OR 0.40),基线泼尼松等效剂量≥20 mg/天与更短总生存相关(OR 3.15)。
要点
- 88例复发胶质瘤患者中45例(51.1%)接受分子导向治疗,靶点包括IDH1/2、BRAF、FGFR1突变、FGFR2-3融合及错配修复缺陷。
- 高级别胶质瘤(n=74)中,分子导向组疾病稳定≥6个月及部分或完全缓解率为25.7%,非分子导向组为5.1%(p=0.02)。
- 分子富集策略与更长总生存相关(OR 0.40 [95% CI 0.22-0.73],p=0.003);基线泼尼松等效剂量≥20 mg/天与更短总生存相关(OR 3.15 [95% CI 1.62-6.13],p=0.0008)。
核心结论
- 使用分子谱指导早期临床试验入组是可行的,可能为部分胶质瘤患者带来获益。
- 需要在更大规模随机环境中进一步研究以确认这些结果,并识别最可能从该方法中获益的患者。
研究设计与样本
- 回顾性分析2008至2018年间入组细胞毒治疗、小分子抑制剂或单克隆抗体早期临床试验的复发胶质瘤患者记录。
- 共纳入88例患者,收集临床病理特征、毒性、缓解、无进展生存和总生存数据。
- 主要目的是评估分子导向患者与非分子导向患者的缓解率。
主要发现
- 88例患者中45例(51.1%)为分子导向;靶点包括IDH1/2突变(n=15)、BRAF突变(n=11)、FGFR1突变(n=3)、FGFR2-3融合(n=9)及错配修复缺陷(n=7)。
- 高级别胶质瘤患者(n=74)中,分子导向组疾病稳定≥6个月及部分或完全缓解率为25.7%,非分子导向组为5.1%(p=0.02)。
- 多因素校正后,基线泼尼松等效剂量≥20 mg/天与更短总生存相关(OR 3.15 [95% CI 1.62-6.13],p=0.0008)。
- 多因素校正后,分子富集策略与更长总生存相关(OR 0.40 [95% CI 0.22-0.73],p=0.003)。
- 9例(10.2%)患者发生3-4级毒性,两个队列均未发生剂量限制性毒性(DLT)。
临床怎么用
- 原文结论未据此给出临床推荐。
局限性
- 原文结论指出需要在更大规模随机环境中进一步研究以确认这些结果。
- 原文结论指出需要进一步研究以识别最可能从该方法中获益的患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Recent studies showed that patients with glioma can safely participate in early phase clinical trials; however, clinical benefits in this population were limited. We aimed to evaluate the benefit of molecular profiling to guide enrolment in early phase trials for patients with recurrent glioma. METHODS: Records of patients enrolled in early phase trials of cytotoxic therapies, small molecule inhibitors or monoclonal antibodies from 2008 to 2018 were reviewed for clinico-pathological characteristics, toxicity, response, progression-free survival and overall survival (OS). The primary objective was to evaluate response rates in molecularly-oriented versus non-molecularly-oriented patients. RESULTS: Eighty-eight patients were enrolled, of whom 45 (51.1%) patients were molecularly-oriented. Targets included IDH1/2 (n = 15), BRAF (n = 11), and FGFR1 (n = 3) mutations, FGFR2-3 fusions (n = 9), and mismatch repair deficiency (n = 7). Among patients with high-grade glioma (n = 74), the rate of stable disease ≥6 months and partial or complete response was 25.7% in molecularly-oriented versus 5.1% in non-molecularly-oriented patients (p = 0.02). Upon multivariable adjustment, baseline steroid use ≥20 mg prednisone equivalent per day was associated with shorter OS (OR 3.15 [95% CI 1.62-6.13], p = 0.0008), while molecular enrichment strategy was associated with longer OS (OR 0.40 [95% CI 0.22-0.73], p = 0.003). Nine (10.2%) patients experienced grade 3-4 toxicity and no dose limiting toxicity (DLT) occurred in both cohorts. CONCLUSION: The use of molecular profiling to guide enrolment in early phase trials is feasible and might provide benefits to selected patients with glioma. Further studies are warranted to confirm these results in larger randomised settings and identify the patients most likely to benefit from this approach.
引用
- Baldini C, Younan N, Castanon Alvarez E, et al. Genome-driven medicine for patients with recurrent glioma enrolled in early phase trials. Eur J Cancer. 2022. PMID: 35063776. doi:10.1016/j.ejca.2021.11.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。